MXPA03001391A - Uso de anticuerpos contra complejos especificos mhc-peptidos. - Google Patents

Uso de anticuerpos contra complejos especificos mhc-peptidos.

Info

Publication number
MXPA03001391A
MXPA03001391A MXPA03001391A MXPA03001391A MXPA03001391A MX PA03001391 A MXPA03001391 A MX PA03001391A MX PA03001391 A MXPA03001391 A MX PA03001391A MX PA03001391 A MXPA03001391 A MX PA03001391A MX PA03001391 A MXPA03001391 A MX PA03001391A
Authority
MX
Mexico
Prior art keywords
antibodies against
specific mhc
peptide complexes
against specific
mhc
Prior art date
Application number
MXPA03001391A
Other languages
English (en)
Inventor
Petrus Gerardus A Steenbakkers
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of MXPA03001391A publication Critical patent/MXPA03001391A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invencion describe un metodo para diagnosticar la actividad de enfermedad autoinmune mediante la deteccion de la presencia de un complejo autoinmune especifico de MHC-peptido en un paciente que sufre de una enfermedad autoinmune. El complejo de MHC-peptido se asocia con artritis reumatoide. Los anticuerpos monoclonales a utilizarse para este metodo tambien se describen. Los anticuerpos tambien pueden utilizarse para propositos terapeuticos.
MXPA03001391A 2000-08-14 2001-08-08 Uso de anticuerpos contra complejos especificos mhc-peptidos. MXPA03001391A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202844 2000-08-14
PCT/EP2001/009136 WO2002014870A2 (en) 2000-08-14 2001-08-08 Use of antibodies against specific mhc-peptide complexes

Publications (1)

Publication Number Publication Date
MXPA03001391A true MXPA03001391A (es) 2004-05-04

Family

ID=8171913

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001391A MXPA03001391A (es) 2000-08-14 2001-08-08 Uso de anticuerpos contra complejos especificos mhc-peptidos.

Country Status (14)

Country Link
US (1) US7320873B2 (es)
EP (1) EP1319184B1 (es)
JP (1) JP2004506901A (es)
CN (1) CN1305906C (es)
AR (1) AR033832A1 (es)
AT (1) ATE368225T1 (es)
AU (2) AU9373501A (es)
BR (1) BR0113213A (es)
CA (1) CA2415353A1 (es)
DE (1) DE60129572T2 (es)
ES (1) ES2290171T3 (es)
IL (2) IL154000A0 (es)
MX (1) MXPA03001391A (es)
WO (1) WO2002014870A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000769A (es) 2001-07-24 2005-09-21 Zhu Zhou Metodos, composiciones y equipos relacionados a quitinasas y moleculas similares a la quitinasa y enfermedad inflamatoria.
CA2567814C (en) * 2004-05-27 2013-07-23 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
WO2007030451A2 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
WO2008089494A2 (en) * 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Methods of use of epsilon inhibitor compounds for the attenuation of pain
WO2009151487A1 (en) * 2008-06-13 2009-12-17 Receptor Logic, Inc. Methods of assaying vaccine potency
US8673300B2 (en) 2009-06-04 2014-03-18 The Regents Of The University Of Colorado, A Body Corporate Therapeutic compositions and methods for the prevention of autoimmune diseases
CN103068396B (zh) * 2010-03-02 2016-07-06 诺沃姆德治疗公司 抑制c5和备解素相互作用的抗-备解素抗体在制备抑制交替途径活化的药剂中的用途
US20130189284A1 (en) * 2010-07-15 2013-07-25 Technion Research & Development Foundation Ltd. Antibodies with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
BR112013000985A2 (pt) 2010-07-15 2017-09-05 Technion Res & Dev Foundation Entidades isoladas de alta afinidade com especificidade semelhante à do receptor de célula t em relação a complexos nativos de mhc classe ii e peptídeos autoantigênicos de descarboxilase do ácido glutâmico (gad)
US20130302329A1 (en) * 2010-09-21 2013-11-14 Trustees Of Boston University Diagnostic tests for immune reactivity with human endothelial cell growth factor
MY159058A (en) 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
US9629848B2 (en) 2011-05-26 2017-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds that modulate autoimmunity and methods of using the same
CN104870474B (zh) 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
AP2016009586A0 (en) 2014-05-29 2016-11-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
EP3247384B1 (en) 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate In vitro method of diagnosis of type 1 diabetes with insulin mimotopes
AU2017236977B2 (en) 2016-03-24 2022-05-26 Immunomolecular Therapeutics, Inc. Methods of treating autoimmune disease
AU2018224094A1 (en) 2017-02-24 2019-09-19 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN111423504B (zh) * 2020-04-17 2021-03-26 安徽高安生物医学科技有限公司 黑色素瘤特异性抗原肽、肽复合物以及人工抗原呈递细胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE153695T1 (de) 1990-11-26 1997-06-15 Akzo Nobel Nv Verfahren zur herstellung von antikörpern
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
WO1995002188A1 (en) * 1993-07-12 1995-01-19 The Regents Of The University Of California Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
WO1998012221A1 (de) * 1996-09-18 1998-03-26 Gerhild Wildner Peptide als diagnostikum und therapeutikum für autoimmunerkrankungen
IL122233A (en) 1996-12-06 2001-04-30 Akzo Nobel Nv Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them

Also Published As

Publication number Publication date
ATE368225T1 (de) 2007-08-15
AU2001293735B2 (en) 2006-05-25
CN1447919A (zh) 2003-10-08
JP2004506901A (ja) 2004-03-04
US7320873B2 (en) 2008-01-22
WO2002014870A3 (en) 2002-08-15
AU9373501A (en) 2002-02-25
DE60129572T2 (de) 2008-04-17
EP1319184A2 (en) 2003-06-18
IL154000A0 (en) 2003-07-31
IL154000A (en) 2010-02-17
CA2415353A1 (en) 2002-02-21
US20040137514A1 (en) 2004-07-15
EP1319184B1 (en) 2007-07-25
ES2290171T3 (es) 2008-02-16
CN1305906C (zh) 2007-03-21
WO2002014870A2 (en) 2002-02-21
AR033832A1 (es) 2004-01-07
BR0113213A (pt) 2003-07-08
DE60129572D1 (de) 2007-09-06

Similar Documents

Publication Publication Date Title
MXPA03001391A (es) Uso de anticuerpos contra complejos especificos mhc-peptidos.
EP0914155A4 (en) PROSTATE SPECIFIC MEMBRANE ANTIGEN MONOCLONAL ANTIBODIES
RS20050198A (en) Therapeutic human anti-il-1r1 monoclonal antibody
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
EP1470146A4 (en) ANTIBODIES AGAINST ANTIGEN MUC18
AU2001261741A1 (en) Diagnosis, prevention and treatment of crohn's disease using the ompc antigen
ATE402192T1 (de) Anti-ccr4 antikörper und fragmente davon
NO990190D0 (no) Immunologisk fremgangsmÕte for pÕvisning av antistoffer rettet mot vevstransglutaminase (TTG), anvendelse av TTG for diagnostiske formÕl og terapikontroll og oralt farmas°ytisk middel inneholdende TTG
BG101024A (en) Monoclonal antibody active against cd44v6
NZ288235A (en) Monoclonal antibody directed against the receptor tyrosine kinase flt4 and use in diagnosis and therapy
WO2001046222A3 (en) Peptides designed for the diagnosis and treatment of rheumatoid arthritis
AU7336400A (en) Diagnostic assay for type 2 heparin-induced thrombocytopenia
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
IT1307864B1 (it) Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di
AU2002341090A1 (en) Use of a protein of the crmp family for treating diseases related to the immune system
IL129236A0 (en) Monoclonal antibodies against a human act and serine protease complex
GB0014878D0 (en) Neurotransmission disorders
MXPA03009138A (es) Produccion de anticuerpos monoespecificos policlonales, contra variantes del receptor activador del plasminogeno de tipo uroquinasa (upar) del4, del5 y del4+5 y su uso para propositos de diagnostico y terapeutico.
MD1656G2 (ro) Metodă de diagnosticare a proceselor autoimune în hepatitele cronice
DE60127935D1 (de) Verfahren zur diagnose der effektivität der xenotypischen antikörpertherapie
UA10262A (uk) Спосіб ультразвукової діагностики стану судин головного мозку
AU2003242814A8 (en) In vitro serological method of diagnosing infective endocarditis
FR2832155B1 (fr) Anticorps stimulant la production d'il-1ra
UA28518A (uk) Спосіб визначення алергену у хворих на лікарську хворобу
UA34205A (uk) Спосіб визначення захисної функції плаценти

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration